![]()
|
|
||||||||
J. Biol. Chem., Vol. 276, Issue 33, 30729-30736, August 17, 2001
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the
Received for publication, March 6, 2001, and in revised form, June 13, 2001
Most mammalian cells have in their plasma
membrane at least two types of lipid microdomains, non-invaginated
lipid rafts and caveolae. Glycosylphosphatidylinositol (GPI)-anchored
proteins constitute a class of proteins that are enriched in rafts but not caveolae at steady state. We have analyzed the effects of abolishing GPI biosynthesis on rafts, caveolae, and cholesterol levels.
GPI-deficient cells were obtained by screening for resistance to the
pore-forming toxin aerolysin, which uses this class of proteins as
receptors. Despite the absence of GPI-anchored proteins, mutant cells
still contained lipid rafts, indicating that GPI-anchored proteins are
not crucial structural elements of these domains. Interestingly, the
caveolae-specific membrane proteins, caveolin-1 and 2, were
up-regulated in GPI-deficient cells, in contrast to flotillin-1 and
GM1, which were expressed at normal levels. Additionally, the number of
surface caveolae was increased. This effect was specific since recovery
of GPI biosynthesis by gene recomplementation restored caveolin
expression and the number of surface caveolae to wild type levels. The
inverse correlation between the expression of GPI-anchored proteins and
caveolin-1 was confirmed by the observation that overexpression of
caveolin-1 in wild type cells led to a decrease in the expression of
GPI-anchored proteins. In cells lacking caveolae, the absence of
GPI-anchored proteins caused an increase in cholesterol levels,
suggesting a possible role of GPI-anchored proteins in cholesterol
homeostasis, which in some cells, such as Chinese hamster ovary
cells, can be compensated by caveolin up-regulation.
According to the current view, the plasma membrane of
mammalian cells is not a homogeneous sea of lipids but is composed of different domains with different lipid and protein compositions and
different physical states. In particular, increasing evidence supports
the existence of cholesterol and glycosphingolipid rich domains, which
have been termed lipid rafts (1, 2). Rafts are physiologically
important since they have been implicated in signaling (3, 4), cell
adhesion (5), and cholesterol homeostasis (4, 6, 7), as well as in
pathological processes such as proteolytic processing of the amyloid
precursor protein (8, 9) or infection by microorganisms (10).
Lipid rafts are small (50-350 nm in diameter depending on the study,
cell type, and analysis method) and highly dynamic entities (11). Due
to the high abundance of cholesterol and lipids with long saturated
acyl chains, the lipid bilayer within these domains is in the tightly
packed liquid ordered state Lo (12). Some proteins preferentially
partition into Lo phases, leading to a specific protein composition
(2). More than 100 proteins have been suggested to be associated with
lipid rafts. Even though this might be an overestimation, considering
the small size of elementary raft units, a given raft can only contain
a limited number of these proteins. It is not clear at present whether
each raft contains a random sample of raft components or whether some rafts contain a specific set of proteins or lipids, i.e.
whether there are different types of rafts.
A clear subclass of rafts is, however, composed by caveolae (13). These
can easily be distinguished by their shape (they are flask-like
invaginations) and by the presence of membrane proteins of the caveolin
family (4, 7, 13). The proposed functions of caveolae are similar to
those attributed to rafts. They are believed to be implicated in signal
transduction, based on the observation that caveolin-1 interacts with a
number of signaling molecules (14), and in cholesterol regulation (4, 7). In the present paper, for the sake of clarity, the term raft will
only be used to identify all non-caveolar rafts, as opposed to caveolae
themselves. In contrast to rafts, caveolae are not ubiquitous since
they are not found in cells lacking caveolins such as lymphocytes (15).
However, heterologous expression of caveolin-1 will induce de
novo formation of caveolae (16-18).
A class of raft proteins that has attracted much attention over the
last decade is that of
GPI1-anchored proteins
(GPI-APs). These lipid-anchored polypeptides are mainly present at the
plasma membrane where they are found in rafts, i.e. outside
of caveolae, at steady state (19), even though they may enter caveolar
pits upon cross-linking with antibodies (20). GPI-anchored proteins,
however, also undergo endocytosis. In CHO cells, they were shown to be
internalized and then recycled back to the plasma membrane via the
recycling endosome (21)2 in a
cholesterol-dependent (21) and
sphingolipid-dependent (22) process. In COS-7 cells,
although GPI-anchored proteins were found to cycle between the plasma
membrane and the Golgi apparatus, trafficking was again found to be
cholesterol-dependent (23), further highlighting the
functional interactions between GPI-APs and cholesterol.
We here investigated whether the absence of GPI-anchored
proteins would affect lipid rafts and/or caveolae. We have used
GPI-deficient lymphocytes and CHO cells. The GPI-deficient CHO cells
were obtained by screening for resistance toward the bacterial
pore-forming toxin aerolysin, which binds specifically to GPI-APs
(24-26). Interestingly, we found that GPI-deficient CHO cells express
higher levels of caveolin-1 than wild type cells, due to increased
transcription, and concomitantly have an increased number of caveolae
at their surface. Restoration of GPI biosynthesis by gene
recomplementation subsequently reduced caveolin-1 expression to wild
type levels. These experiments indicate that cells that lack
GPI-anchored proteins somehow compensate for this loss by
overexpressing caveolins. Comparison of GPI-deficient cells, which
naturally express caveolins (CHO) or lack caveolins (lymphocytes),
suggests that caveolin overexpression might compensate for cholesterol defects.
Materials--
Monoclonal anti-caveolin-1 and anti-caveolin-2
antibodies were purchased from Transduction Laboratories (Lexington,
KY), polyclonal anti-caveolin-1 N20 antibodies from Santa Cruz,
monoclonal anti-transferrin receptor antibodies from Zymed
Laboratories Inc., polyclonal anti-LAT from Upstate Biotechnology
(Lake Placid, NY), and monoclonal mouse anti-FLAG antibodies from Sigma
and horseradish peroxidase-conjugated secondary antibodies from
Amersham Pharmacia Biotech. Anti-Rab 5, anti- Proaerolysin Purification, Iodination, and
Activation--
Proaerolysin was purified as described previously
(30). Concentrations were determined by measuring the optical density at 280 nm, considering that a 1 mg/ml sample has an optical density of
2.5 (31). Proaerolysin was labeled with 125I using IODOGEN
reagent (Pierce) according to the manufacturer's recommendations. The
radiolabeled toxin was separated from the free iodine by gel filtration
on a PD10-G25 column (Amersham Pharmacia Biotech) equilibrated with 150 mM NaCl, 20 mM HEPES, pH 7.4. We consistently
obtained a specific activity of about 2 × 106
cpm/µg of proaerolysin. Radiolabeled proaerolysin ran as a single band on a SDS gel.
Cell Culture and Isolation of Proaerolysin-resistant
Mutants--
CHO-K1 cells were routinely maintained in 100-mm diameter
Nunc dishes containing 10 ml of F-12 medium supplemented with 10% fetal calf serum and 2 mM L-glutamine under
standard tissue culture conditions in a 5% CO2 atmosphere
at 100% humidity at 37 °C. CHO-K1 cells were mutagenized with ethyl
methanesulfonate (400 µg/ml) at 37 °C for 24 h, as described
(32). After growing in the complete culture medium for 4 days, the
mutagenized cells were harvested, re-seeded at 400 colonies/dish, and
grown in the presence of 1 nM proaerolysin for another 2 days. After incubation in toxin-free culture medium for 7 days,
surviving colonies were trypsinized with a filter paper and transferred
to 24-well plates. The cells were cultured in normal medium for several
days, re-seeded, and then subjected to two other cycles of proaerolysin
selection as above. A total of 314 separated colonies of surviving
cells were formed and purified by limited dilution. After confirming
toxin resistance, clones were frozen for further analysis.
Proaerolysin Binding--
Confluent monolayers of CHO cells were
washed three times with ice-cold PBS containing 1 mM
CaCl2 and 1 mM MgCl2
(PBS2+). Cells were then incubated at 4 °C with 0.4 or
0.96 nM 125I-proaerolysin in incubation medium
containing Glasgow minimal essential medium buffered with 10 mM HEPES, pH 7.4, for 1 h. Cells were washed three
times for 5 min with PBS2+ at 4 °C. Monolayers were then
further incubated at 37 °C in incubation medium for various times.
Cells were subsequently washed with ice-cold PBS2+, scraped
from the dish, and collected by centrifugation at 300 × g for 5 min. The presence of cell-bound
125I-proaerolysin was analyzed either by counting or by
autoradiography of 10% SDS gels.
Proaerolysin Overlays--
Proaerolysin overlays, to detect
proaerolysin receptors, were performed as described previously (25).
Briefly, membrane fractions were run on a 10% SDS gel (33). The gel
was incubated in 50 mM Tris-HCl, pH 7.4, and 20% glycerol
for 10 min. Proteins were then blotted onto a nitrocellulose membrane
for 16 h at 100 mA in the cold using a Bio-Rad wet transfer
chamber with a transfer buffer containing 10 mM
NaHCO3 and 3 mM Na2CO3
(pH 9.8). The nitrocellulose membrane was incubated in a binding buffer
containing 50 mM NaH2PO4, pH 7.5, and 0.3% Tween 20 for 20 min, followed by a 2-h incubation in the
presence of 2.8 nM proaerolysin (labeled or not with
125I) diluted in the same buffer. The membrane was then
washed six times for 5 min with toxin free binding buffer. Binding of
proaerolysin was revealed by autoradiography using BioMax films
(Eastman Kodak Co.) or using anti-aerolysin antibodies.
Plasmids, Transfections, and Generation of Stable Cell
Lines--
PIG-L and PIG-A genes were expressed in a pMEori expression
vector (pME-EBO-FLAG) driven by Sr- Purification of Detergent-resistant Membranes
(DRMs)--
Approximately 2 × 107 cells were
resuspended in 0.5 ml of cold buffer (TNE) containing 25 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 5 mM EDTA, and
1% Triton X-100 (Ultrapure, Pierce) with a tablet of Complete (Roche
Molecular Biochemicals), a mixture of protease inhibitors. Membranes
were solubilized by rotary shaking at 4 °C for 30 min. The DRMs were
purified on either a step sucrose gradient (25) or using an Optiprep
gradients (35). For purification on sucrose gradients, the cell lysate
was adjusted to 40.7% sucrose (in 10 mM Tris-HCl, pH 7.4),
loaded at the bottom of a SW 40 Beckman tube, overlaid with 8 ml of
35% sucrose, topped up with 15% sucrose, and centrifuged for 18 h at 35,000 rpm at 4 °C. After centrifugation, 12 fractions of 1 ml
were collected. For each fraction the protein content was determined.
The same protein amount of each fraction was precipitated and analyzed
by SDS-PAGE, followed by toxin overlay and/or Western blot analysis.
For purification on Optiprep gradients, the cell lysate was adjusted to
40% Optiprep, loaded at the bottom of a TLS.55 Beckman tube, overlaid
with 600 µl of 30% Optiprep and 600 µl of TNE, and centrifuged for
1.5 h at 55,000 rpm at 4 °C. Six fractions of 250 µl were
collected from top to bottom. DRMs were found in fraction 3, which were
subsequently precipitated with chloroform methanol and analyzed as above.
Two-dimensional Gel Analysis--
DRMs were prepared from wild
type and mutant CHO cells as described (36) and precipitated with 6%
trichloroacetic acid in the presence of 375 µg of sodium deoxycholate
as a carrier. Two-dimensional gel electrophoresis was performed with
non-linear immobilized pH gradient strips, pH range 3-10 (Amersham
Pharmacia Biotech, Uppsala, Sweden) as described (36, 37).
Northern Blotting of Caveolin mRNA--
Total RNA was
purified from CHO wild type or LA1 cell monolayers with Nucleospin RNA
II kits (Macherey-Nagel). Confluent cells in one 10-cm dish yielded
~10 µg of total RNA. For Northern blot analysis, 1.25 µg of RNA
were separated on 1% agarose/formaldehyde denaturing gel and
transferred on to a nylon membrane. The membrane was stained with
methylene blue (presence of 28 and 18 S ribosomal RNA bands indicating
intact RNA) and was hybridized to full-length random-primed
32P-labeled (random-primed DNA labeling kit, Roche
Molecular Biochemicals) caveolin cDNA
(EcoRI-XhoI insert of 890 base pairs). The
caveolin blot was prehybridized for 24 h at 65 °C and then
hybridized overnight at 65 °C to the probe at 1 × 10.6 cpm/ml
hybridization buffer. Washed blots were visualized on Kodak X-Omat
film, exposed to a phosphorimager plate, and analyzed using Quantity
One software (Bio-Rad) under conditions where the signals were linear
with respect to the amount of sample applied.
Immunofluorescence--
Fixation and permeabilization of CHO
cells were performed by incubation 4 min at Cholesterol Quantification by Thin Layer
Chromatography--
Lipids were chloroform/methanol-extracted from
cell extract (equivalent of 40 µg of protein). Lipids were separated
on Kiesel gel 60 (Merck, Germany) with a solvent system of
heptane:ethyl ether:acetic acid (18:6:2). Cholesterol was visualized
after incubating the sheet in a solution of 3% copper acetate with 8%
H3PO4 and drying 5 min at 160 °C. TLC plates
were then analyzed by densitometry and cholesterol amount quantified
using Scan-Analysis software.
Other Methods--
To quantify cell growth, wild
type and mutant CHO cells were seeded in complete medium at the density
of 4.105 cells/ml at day 0 and counted every 24 h.
Cell surface caveolae were quantitated by electron microscopy exactly
as described previously (38). SDS-PAGE was performed as described by
Laemmli (33). Western blot analysis was carried out using
peroxidase-conjugated sheep anti-mouse or anti-rabbit IgG as a
secondary antibody, which was detected by chemiluminescence using Super
Signal reagents (Pierce). Protein concentrations of cellular fractions
were determined with bicinchoninic acid (BCA, Pierce).
Generation of CHO Mutant Cell Lines Deficient in GPI
Biosynthesis--
In order to generate cell deficient in GPI
biosynthesis, we have made use of the bacterial pore-forming toxin
aerolysin (26). This toxin specifically binds to GPI-anchored proteins
on mammalian cells, and the binding capacity is retained after SDS-PAGE
of cellular extracts and blotting onto a nitrocellulose membrane (toxin
overlay assay) (24, 25). The main determinant for aerolysin binding is
not the protein moiety but the glycan core common to all GPI-anchored
proteins (39). Therefore, aerolysin does not generally discriminate
between different GPI-anchored proteins, although some exceptions exist
(40). Thus, all cells expressing GPI-anchored proteins are likely to be
sensitive to aerolysin and will ultimately dye when exposed to the
toxin (25). Conversely, cells lacking GPI-anchored proteins should be
insensitive to aerolysin, as suggested by several examples (40, 41) and
should therefore multiply even in the presence of the toxin. Aerolysin
therefore potentially constitutes a very powerful tool to generate
GPI-deficient cells. We found that this is indeed the case by screening
for aerolysin-resistant CHO cells. We have recently identified and characterized the GPI-anchored protein composition of CHO cells by
two-dimensional gel analysis2 and shown that a protein with
apparent molecular mass of 130 kDa is by far the most abundant
GPI-anchored protein in this cell type. This protein, called here
GPI-130, can readily be detected by performing an aerolysin overlay
assay on a postnuclear supernatant after one-dimensional SDS-PAGE (can
be seen in Fig. 1B).
Cells were submitted to chemical mutagenesis with EMS and then selected
for the ability to grow in the presence of 1 nM
proaerolysin, the aerolysin precursor (for review see Ref. 26). Among
314 mutants, most were unable to bind aerolysin (Fig. 1A)
and 9 were selected for further analysis. In agreement with the lack of
proaerolysin binding, we could not detect GPI-130 by toxin overlay in
any of the mutants (identified by numbers in Fig.
1B). The absence of GPI-130 suggested that the cells might
indeed be deficient in the biosynthesis of GPI-anchored proteins in
general. This was confirmed by the observation that none of the mutants
were able to heterologously express the GPI-anchored protein human
alkaline phosphatase (data not shown).
CHO mutants deficient in GPI biosynthesis have previously been
generated by EMS mutagenesis (for reviews see Refs. 42 and 43). Most of
the obtained mutants were deficient in the enzyme responsible for the
N-deacetylation of N-acetylglucosamine
phosphatidylinositol, which is encoded by the PIG-L gene (27, 44). We
therefore tested whether our mutants were also PIG-L-deficient, by
transfecting cells with a PIG-L construct. Expression of alkaline
phosphatase and sensitivity toward proaerolysin were assayed. Among the
nine selected mutants, only the CHO-LA1 mutant cell line (labeled
1 in Fig. 1B) was sensitive toward proaerolysin
after PIG-L transfection, as witnessed by a recovery of ER vacuolation,
a characteristic effect of aerolysin on fibroblast-like cells (25, 45)
(Fig. 2A). A second frequent
target gene of EMS mutagenesis is the DMP2 gene, encoding an ER protein
implicated in the synthesis of dolichol-phosphate mannose, a mannose
donor for GPI as well as for N-glycans and C-mannosylation
(46). By gene recomplementation, we found that mutant CHO-LA49 (labeled
49 in Fig. 1B) was affected in the DMP2 gene. It
remains to be determined what step of GPI biosynthesis is affected in
the other mutant cells.
Characterization of the CHO-LA1 GPI-deficient Cell Line--
The
CHO-LA1 GPI-deficient cell line was chosen for further analysis, and a
stable CHO-LA1 cell line expressing the PIG-L gene was generated. In
agreement with their sensitivity toward aerolysin (Fig. 2A),
CHO-LA1 cells recomplemented with the PIG-L gene were able to express
GPI-130 (Fig. 2B).
We first checked that the absence of GPI-anchored proteins
did not drastically affect cellular physiology. As shown in Fig. 3A, the growth curve of
CHO-LA1 was similar to that of wild type and PIG-L recomplemented
cells. We next verified that a variety of proteins involved in key
cellular functions were expressed to normal levels. The
The above observations suggest that the absence of GPI-anchored protein
does not grossly alter the physiology of CHO cells in culture. This
contrasts with the importance of GPI-anchored proteins in mouse
embryonic development (54).
Existence of Rafts in GPI-deficient Cells--
We next
investigated whether the absence of GPI-anchored proteins affected raft
integrity. Since rafts have the biochemical property of being resistant
to certain non-ionic detergents at 4 °C, we have analyzed whether
DRMs could be purified by flotation gradients from CHO-LA1 as from wild
type CHO cells. As shown in Fig.
4A, DRMs could readily be
obtained from mutant cells and were enriched in caveolin-1 as well as
flotillin-1, a protein reported to be associated with caveolae and
other subdomains of the plasma membrane (55-57). Note that after
purification of DRMs, two additional GPI-anchored proteins could be
detected by toxin overlay in wild type cells, GPI-40, and GPI-60. The
protein composition of DRMs from wild type and GPI-deficient cells was
very similar as witnessed by two-dimensional gel analysis (Fig.
4B).
The only detectable different between DRMs from wild type and
GPI-deficient cells as analyzed in Fig. 4A was that the
latter contained more caveolin-1. This raised the possibility that
CHO-LA1 cells might have fewer or no rafts and compensate for this loss by forming a greater number of caveolae. Since both rafts and caveolae
are found in DRMs, the analysis of DRMs of CHO cells does not allow to
address this issue.
We therefore analyzed lymphocytes since they lack caveolae (15). DRMs
were prepared from control lymphocytes (BW5147) and mutants, which are
deficient in the first step of GPI biosynthesis, i.e. the
transfer of N-acetylglucosamine to phosphatidylinositol (58)
(BW5147/A; Ref. 59). As raft markers, we have used flotillin-1 and the
transmembrane protein linker for activation of T cells (LAT) (60). As
shown in Fig. 5, DRMs, enriched in
flotillin-1 and LAT, could be obtained from both wild type and
GPI-deficient lymphocytes, indicating that GPI-anchored proteins are
not necessary for the structural integrity of rafts. Since BW5147/A
cells are mutated in the first step in GPI biosynthesis (42, 58), these cells also lack non-protein-linked or so-called free GPIs. These free
glycolipids are abundant in many mammalian cells (105 to
107 molecules/cell; Ref. 61), and are found at the plasma
membrane as well as in intracellular organelles (62). The physiological role of free GPIs is not known. They are, however, likely to
concentrate in rafts since they share the same lipid moiety as
GPI-anchored proteins. The present observations demonstrate that not
only GPI-anchored proteins but also free GPIs are not required for raft
integrity.
Increased Expression of Caveolin-1 in GPI-deficient Cell
Lines--
The observation that caveolin-1 was more enriched in DRMs
of CHO-LA1 cells than in those of wild type cells (Fig. 4A)
could be due to a stronger association of caveolin-1 with DRMs in the mutant cells or to higher expression levels of this protein. We therefore compared the amounts of caveolin-1 in postnuclear
supernatants of wild type and CHO-LA1 cells. Care was taken to perform
experiments on wild type and mutant cells that were at similar
confluence since cell confluence can affect the level of caveolin-1
expression (63). As shown in Fig.
6A, the total amount of
caveolin-1 was higher in CHO-LA1 cells but was restored to normal
levels upon expression of the PIG-L gene, but not of the PIG-A gene
(data not shown). The increase in caveolin-1 in LA1 cells was
accompanied by an up-regulation of caveolin-2 (Fig. 6A). The
levels of other markers of DRMs such as flotillin-1 and GM1 were,
however, not affected (Fig. 6A), suggesting that the absence
of GPI-anchored protein specifically affects caveolin levels.
According to this hypothesis, all mutant cell lines deficient in GPI
biosynthesis should express higher levels of caveolin-1 than wild type
cells, independently of the gene in the GPI biosynthesis that is
mutated. As shown in Fig. 6B, this is indeed the case: all
our previously mentioned GPI-deficient cell lines (which no longer
express GPI-130, as shown in Fig. 1, or exogenous alkaline phosphatase)
showed increased levels of caveolin-1. One possibility could have been
that the increase of caveolin-1 is not due to the absence of
GPI-anchored proteins but rather to the accumulation of GPI
intermediates. This seems unlikely for the following reasons. First,
CHO-LA1 and CHO-LA49 are mutated in two proteins involved in the early
steps of GPI biosynthesis and therefore accumulate GlcNAc-PI but not
mannosylated intermediates. Second, although CHO-LA49 cells are likely
to accumulate less GlcNAc-PI then CHO-LA1 (see reason below), they
express similarly high levels of caveolin-1 as CHO-LA1 cells. As
mentioned above, CHO-LA49 cells were affected in DPM2, a protein that
has been shown to regulate the GPI-N-acetyl glucosaminyltransferase (64). In the absence of DPM2, the enzyme activity of GPI-N-acetyl glucosaminyltransferase was found
to be reduced by 3-fold leading to a decreased production of the GPI
intermediate GlcNAc-PI.
Increase in the Number of Caveolae in GPI-deficient CHO-LA1
Cells--
Up-regulation of caveolin-1 has been shown previously to be
accompanied by an increase in the number of caveolae (38, 65, 66).
Immunofluorescence analysis of wild type and CHO-LA1 suggested that
indeed the number of caveolae was higher in the GPI-deficient cells
(Fig. 7A) since the punctate
staining pattern appeared more intense and dense for CHO-LA1 cells.
This was confirmed when analyzing the cells by electron microscopy.
Non-coated 50-100-nm flask-shaped invaginations at the plasma
membrane, typical of caveolae, were counted for each cell type. CHO-LA1
cells had almost twice as many caveolae as wild type (Table
I). Importantly, the number of caveolae
returned to wild type levels when LA1 cells were recomplemented with
the PIG-L gene.
This higher expression of caveolin-1 in CHO-LA1 is most likely due to
an increase in transcription since the level of caveolin-1 mRNA was
increased by 2.5-fold when compared with wild type cells, as determined
by Northern blot analysis using a caveolin-1 cDNA probe (Fig.
7B). We cannot, however, exclude that mRNA stability was increased.
Inverse Correlation between the Levels of Caveolin-1 and of
GPI-anchored Proteins--
The above experiments show that the absence
of GPI-anchored proteins leads to an up-regulation of caveolins and an
increase in the number of caveolae. To confirm this apparent inverse
correlation, we tested whether overexpression of caveolin-1 would lead
to a reduction of the amount of GPI-anchored proteins. Two cell lines, CHO C1 and C3, were generated that overexpress caveolin-1 to different extents, which are, however, lower than CHO-LA1 GPI minus cells (Fig.
8). As shown in Fig. 8, the increase in
caveolin-1 levels was accompanied by a decrease in the amounts of
GPI-anchored proteins (GPI-130, GPI-60, and GPI-40) as well as an
expected decrease in aerolysin binding (Fig. 8B).
The inverse correlation we have observed here between caveolin-1 and
GPI-anchored protein expression is consistent with the previous
observations that a reduction in caveolin-1 in ovarian carcinoma leads
to an increase in the levels of GPI-anchored folate receptor (67) and
that the overexpression of placental alkaline phosphatase in baby
hamster kidney cells leads to a decrease in caveolin-1 levels (data not shown).
Effect of GPI Deficiency on Total Cholesterol
Content--
Finally, since GPI-anchored proteins are enriched in
cholesterol-rich membranes and since cholesterol appears to regulate transport of GPI-APs (21, 23), we wondered whether the absence of
GPI-anchored proteins would affect total cholesterol contents. As shown
in Fig. 9, all our CHO GPI-deficient cell
lines (described in Figs. 1 and 6) had total cholesterol contents
similar to those for wild type cells. Since caveolin-1 has been shown
to play a role in cholesterol homeostasis (6, 7), the maintenance of
wild type cholesterol levels in GPI-deficient CHO cells could be due to
the increased amount of caveolins. To test this possibility, we
measured total cholesterol levels in wild type and GPI-deficient BW5147
lymphocytes. As shown in Fig. 9, class A lymphocytes had a 2.1-fold
higher cholesterol level than wild type cells. Taken together, the
above observations support the hypothesis that caveolins are
up-regulated in GPI-deficient CHO cells in response to cholesterol changes.
Conclusions--
We here show that GPI-anchored proteins as well
as free GPIs are not required for the structural integrity of lipids
rafts. In agreement with our observations, it was recently shown (68) that erythrocytes from patients with paroxysmal nocturnal
hemoglobinuria, which lack glycosylphosphatidylinositol-anchored
proteins (mutation in PIG A gene), still contained rafts.
Interestingly, we found that in the absence of GPI-anchored proteins,
lymphocytes had elevated levels of cholesterol. Similar observations
were made on paroxysmal nocturnal hemoglobinuria erythrocytes, which
were found to have 2.37 times more cholesterol than control
erythrocytes (68). In contrast, we found that CHO cells stringently
maintain their cholesterol levels in the absence of GPI-anchored
proteins. One possible explanation for the differences observed between
lymphocytes and erythrocytes, on one hand, and CHO cells, on the other,
is that the latter cells contain caveolins, which have been implicated
in cholesterol homeostasis. Strikingly, GPI-deficient CHO cells express
higher levels of caveolins than wild type cells and have more caveolae
at their plasma membrane. It is therefore tempting to speculate that
caveolins are up-regulated in GPI-deficient cells in response to
cholesterol changes. Further investigation will be required to confirm
the hypothesis that GPI deficiency affects cholesterol regulation, in a
manner that can be compensated for by caveolins.
We are very grateful to Robert Hyman for
providing us with GPI-deficient lymphocytes. We thank Filipo Passardi
for contributions toward this work during short term training in the
laboratory. We thank Paul Dupree for caveolin-1 cDNA; Perry Bickel
for the anti-flotillin-1 antibodies; Marie-Claire Velluz, Margaret
Lindsay, and Kathryn Green for technical assistance; and Jean Gruenberg and Frank Lafont for critical reading of the manuscript.
*
This work was supported by a grant from the Swiss National
Science Foundation (to F. G. v. d. G. and J. P.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
**
To whom correspondence should be addressed. Tel.:
41-22-702-6032; Fax: 41-22-702-6414; E-mail:
gisou.vandergoot@biochem.unige.ch.
Published, JBC Papers in Press, June 13, 2001, DOI 10.1074/jbc.M102039200
2
M. Fivaz, F. Vilbois, S. Thurnheer, C. Pasquali,
L. Abrami, P. E. Bickel, and F. G. van der Goot, submitted for publication.
The abbreviations used are:
GPI, glycosylphosphatidylinositol;
CHO, Chinese hamster ovary;
PAGE, polyacrylamide gel electrophoresis;
EMS, ethylmethane sulfonate;
GPI-AP, glycosylphosphatidylinositol-anchored protein;
PNS, postnuclear
supernatant;
DRM, detergent-resistant membrane;
PI, phosphatidylinositol;
PBS, phosphate-buffered saline.
Cross-talk between Caveolae and Glycosylphosphatidylinositol-rich
Domains*
,
,
§,
, and
**
Department of Biochemistry, University of
Geneva, 30 quai E. Ansermet, 1211 Geneva 4, Switzerland, the
§ Supra-Biomolecular System Research Group, RIKEN Frontier
Research System, Saitama 351-0198, Japan, the ¶ Department of
Immunoregulation, Research Institute for Microbial Diseases, Osaka
University, Osaka 565-0871, Japan, and the
Institute for
Molecular Bioscience, Centre for Microscopy & Microanalysis, and
Department of Physiology & Pharmacology, University of Queensland,
Brisbane, Queensland 1072, Australia
![]()
ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
-COP, anti-p23,
anti-
1-
2 adaptins, anti-calnexin, and anti-flotillin antibodies
were gifts from R. Jahn (MPI, Tübingen), the late T. Kreis, J. Gruenberg (University of Geneva, Geneva), A. Dautry-Varsat (Pasteur
Institute, Paris), A. Helenius (ETH, Zürich), and P. Bickel
(Harvard, Cambridge, MA), respectively. Fluorescent secondary
antibodies were from Jackson Immunoresearch. Peroxidase-coupled cholera
toxin B-subunit was purchased from Sigma. cDNAs of PIG-L and PIG-A
were those previously generated (27, 28). The caveolin-1 cDNA was a
gift from P. Dupree (University of Cambridge, Cambridge)
(29).
promoter composed of human T-cell lymphotrophic virus-1 enhancer and simian virus 40 early promoter (27). Caveolin-1 gene was introduced in the pcDNA3 vector
driven by the human cytomegalovirus promoter. Plasmids were purified
using columns (Quiagen Inc., Chatsworth, CA) according to the
manufacturer's instructions. Transfection experiments in CHO cells
were performed by the CaPO4-DNA precipitation procedure described by Graham and van der Eb (34), using caveolin-1, PIG-L, or
PIG-A expression constructs. CHO cells from a confluent
60-cm2 tissue culture dish were diluted 1:15 and seeded on
glass coverslips in a six-well tissue culture plate in view of
immunofluorescence experiments. Per well, 3 µg of plasmid DNA were
used. The expressing cells were analyzed by immunofluorescence after
48 h of incubation at 37 °C. To establish stable cell lines
expressing FLAG-PIGL or FLAG-PIGA, transfectants were selected with
culture medium containing 200 µg/ml hygromicin. Stable cell lines
expressing caveolin-1 were selected for resistance toward 600 µg/ml
G418. After three cycles of trypsinization and antibiotic treatment, colonies were isolated by limited dilution.
20 °C in methanol.
After three washes in PBS plus 0.05% bovine serum albumin, fixed cells
were reacted for 30 min at room temperature with polyclonal
anti-caveolin 1 antibodies (1:100). Cells were then washed three times
with PBS, 0.5% bovine serum albumin and incubated for 30 min at room
temperature with fluorescein isothiocyanate-conjugated goat anti-rabbit
IgG (1:50). Cells were analyzed with a Zeiss Axiophot fluorescence microscope.
![]()
RESULTS AND DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES

View larger version (47K):
[in a new window]
Fig. 1.
Proaerolysin-resistant CHO mutant cell lines
can no longer bind the toxin due to the loss of the cell surface
GPI-anchored receptors. A, histogram of
125I-proaerolysin binding. Monolayers of CHO wild type and
mutant cells were incubated with 125I-proaerolysin (1 nM) for 1 h at 4 °C, extensively washed, and
incubated for an additional 20 min at 37 °C. The amount of
radioactivity associated with the cells was counted and expressed as a
percentage of the CHO wild type associated radioactivity
(n = 4). The numbers refer to the name of
mutant cell lines obtained after screening for aerolysin resistance
(see text). B, absence of GPI-130 in proaerolysin
binding-deficient CHO mutants revealed by proaerolysin overlay. 40 µg
of postnuclear supernatant of each cell type were submitted to a
proaerolysin overlay assay.

View larger version (47K):
[in a new window]
Fig. 2.
Recovery of proaerolysin sensitivity upon
transfection of CHO-LA1 cells with the PIG-L gene. A,
effect of proaerolysin on the morphology of CHO-LA1 in the absence
(left) or presence (right) of the PIG-L gene.
Cells were incubated with 0.4 nM proaerolysin at 37 °C
for 1 h. Bar = 10 µm. B, recovery of
GPI biosynthesis upon transfection of CHO-LA1 cells with the PIG-L
gene. GPI-anchored proteins were detected by aerolysin overlay on PNS
(40 µg) of wild type cells, CHO-LA1, and CHO-LA1 recomplemented with
the PIG-L gene. Calnexin was used as an equal loading marker.
1-
2
adaptins, implicated in clathrin-mediated vesicular transport (47), and
the small GTPase Rab5, involved in early steps of endocytosis (48),
were expressed to similar levels in wild type and GPI-deficient LA1
cells (Fig. 3B). Also levels of transferrin receptor and of
-COP, one of the components of the COPI coat involved biosynthetic
and endocytic transport (49, 50), were similar in wild type and mutant
cells (Fig. 3B). Finally, we analyzed the levels of p23, a
type I membrane protein that has been implicated in organizing the
early secretory pathway (51) as well as in transport of GPI-anchored
proteins in yeast (52, 53). Levels of p23 were also similar in wild type and mutant cells (Fig. 3B).

View larger version (19K):
[in a new window]
Fig. 3.
Characterization of CHO-LA1 cells.
A, growth of GPI-deficient CHO-LA1 cells was found to be
indistinguishable from that of wild type and PIG-L recomplemented
cells. Values represent the mean of three experiments. B,
PNS were prepared from wild type cells, CHO-LA1, and CHO-LA1
recomplemented with the PIG-L gene. Western blot analysis (40 µg of
protein loaded/lane) shows that cellular levels of
1-
2 adaptins,
the small GTPase Rab5, the transferrin receptor (Tf-R),
-COP, and p23, one of the p24 family members, were similar in wild
type, mutant, and recomplemented cells.

View larger version (71K):
[in a new window]
Fig. 4.
Isolation of detergent-resistant membranes
from wild type and CHO-LA1 cells. DRMs were purified from wild
type and CHO-LA1 cells using sucrose flotation gradients. A,
fractions were collected from the top to the bottom of the gradient and
equal amounts of proteins (20 µg) from each fraction were separated
by SDS-PAGE and blotted onto nitrocellulose. The distribution of
GPI-anchored proteins was analyzed by aerolysin overlay and that of
caveolin-1, flotillin-1, and the transferrin receptor (Tf-R)
by Western blotting. B, the two-dimensional protein map of
DRMs from wild type and LA1 CHO cells were obtained by two-dimensional
gel electrophoresis followed by high sensitivity silver staining. The
repeated two-dimensional gel analysis of DRMs from the two cell types
as well as the comparison of the gels using the MELANIE two-dimensional
gel analysis software indicated that the protein patterns were
essentially identical. GPI-anchored proteins are not detectable on the
gel of CHO wild type cells, because the DRMs were not treated with
PI-phospholipase C (36) prior to two-dimensional SDS-PAGE and,
moreover, CHO GPI-anchored proteins are not abundant enough to be seen
on such a gel. IEF, isoelectric focusing; IPG, immobilized pH
gradient.

View larger version (61K):
[in a new window]
Fig. 5.
Isolation of DRMs from
lymphocytes expressing or not expressing GPI-anchored proteins.
DRMs were purified from wild type and class A BW5147 cells using
sucrose flotation gradients. Fractions were collected from the top to
the bottom of the gradient, and equal amounts of proteins (20 µg)
from each fraction were analyzed by SDS-PAGE and Western blotting using
anti-flotillin and LAT antibodies.

View larger version (48K):
[in a new window]
Fig. 6.
Effects of GPI deficiency on the levels of
raft/caveolae markers. A, PNS were prepared from wild
type cells, CHO-LA1, and CHO-LA1 recomplemented with the PIG-L gene.
The amounts of caveolin-1, caveolin-2 and flotillin were assayed by
Western blot analysis (40 µg of total protein/lane). Calnexin was
used as an equal loading marker. The amounts of GM1 were analyzed by
dot blot using peroxidase-coupled cholera toxin B-subunit.
B, PNSs were prepared from wild type and various
GPI-deficient cell lines (the numbers refer to the mutant
cell lines, obtained after screening for aerolysin resistance, which no
longer express GPI-130 or alkaline phosphatase (see text and Fig. 1)).
The amounts of caveolin-1was assayed by Western blot analysis (30 µg
of total protein/lane). Calnexin was used as an equal loading
marker.

View larger version (96K):
[in a new window]
Fig. 7.
Up-regulation of caveolin-1 in GPI-deficient
cells. A, the distribution of caveolin-1 was analyzed
by immunofluorescence on wild type and CHO-LA1 cells. Cells were fixed
and permeabilized with methanol and incubated for 30 min at room
temperature with polyclonal anti-caveolin -1 antibodies, followed by 30 min with fluorescein isothiocyanate anti-rabbit IgGs.
Bars = 10 µm. B, detection of caveolin
mRNA by Northern blot analysis using the full-length caveolin-1 DNA
as probe on 1.25 µg of total RNA of wild type or LA1 CHO cells.
Quantification using a phosphorimager revealed a 2.3-fold increase in
caveolin-1 mRNA (n = 2).
The number of cell surface caveolae is increased in GPI-deficient
CHO cells

View larger version (22K):
[in a new window]
Fig. 8.
Down-regulation of GPI-anchored proteins upon
overexpression of caveolin-1. A, CHO cell lines
overexpressing caveolin-1 (called CHO C1 and C3) to various extents
were generated. The amounts of caveolin-1 in the various cell types
were analyzed by Western blotting (40 µg of protein loaded/lane).
B, the levels of GPI-anchored proteins in
caveolin-1-overexpressing cells was measured by aerolysin overlay on
DRMs prepared using Optiprep gradients. C, histogram of
125I-proaerolysin binding. Monolayers CHO wild type and
caveolin-1-overexpressing cells were incubated with
125I-proaerolysin (0.4 nM) for 1 h at
4 °C and extensively washed. The amount of radioactivity associated
with the cells was counted, normalized to the amount of protein, and
expressed as a percentage of the CHO wild type-associated radioactivity
(n = 4).

View larger version (41K):
[in a new window]
Fig. 9.
Cholesterol levels in GPI-deficient
cells. The total cholesterol content of wild and GPI-deficient CHO
cells as well as wild type and class A BW5147 lymphocytes was measured
by TLC analysis on cell extracts (equivalent of 40 µg of protein).
TLC plates were then analyzed by densitometry (n = 3).
![]()
ACKNOWLEDGEMENTS
![]()
FOOTNOTES
![]()
ABBREVIATIONS
![]()
REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS AND DISCUSSION
REFERENCES
1.
Simons, K.,
and Ikonen, E.
(1997)
Nature
387,
569-572
2.
Brown, D. A.,
and London, E.
(1998)
Annu. Rev. Cell Dev. Biol.
14,
111-136
3.
Janes, P. W.,
Ley, S. C.,
Magee, A. I.,
and Kabouridis, P. S.
(2000)
Semin. Immunol.
12,
23-34
4.
Schlegel, A.,
Pestell, R. G.,
and Lisanti, M. P.
(2000)
Front. Biosci.
5,
D929-37
5.
Kasahara, K.,
Watanabe, K.,
Takeuchi, K.,
Kaneko, H.,
Oohira, A.,
Yamamoto, T.,
and Sanai, Y.
(2000)
J. Biol. Chem.
275,
34701-34709
6.
Fielding, C. J.,
and Fielding, P. E.
(1997)
J. Lipid Res.
38,
1503-1521
7.
Ikonen, E.,
and Parton, R. G.
(2000)
Traffic
1,
212-217
8.
Simons, M.,
Keller, P.,
De, S. B.,
Beyreuther, K.,
Dotti, C. G.,
and Simons, K.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
6460-6464
9.
Lee, S. J.,
Liyanage, U.,
Bickel, P. E.,
Xia, W.,
Lansbury, P. T., Jr.,
and Kosik, K. S.
(1998)
Nat. Med.
4,
730-734
10.
Fivaz, M.,
Abrami, L.,
and van der Goot, F. G.
(1999)
Trends Cell Biol.
9,
212-213
11.
van der Goot, F. G.,
and Harder, T.
(2001)
Semin. Immunol.
13,
89-97
12.
London, E.,
and Brown, D. A.
(2000)
Biochim. Biophys. Acta
1508,
182-195
13.
Parton, R. G.
(1996)
Curr. Opin. Cell Biol.
8,
542-548
14.
Okamoto, T.,
Schlegel, A.,
Scherer, P. E.,
and Lisanti, M. P.
(1998)
J. Biol. Chem.
273,
5419-5422
15.
Fra, A. M.,
Williamson, E.,
Simons, K.,
and Parton, R. G.
(1994)
J. Biol. Chem.
269,
30745-30748
16.
Fra, A. M.,
Williamson, E.,
Simons, K.,
and Parton, R. G.
(1995)
Proc. Natl. Acad. Sci. U. S. A.
92,
8655-8659
17.
Lipardi, C.,
Mora, R.,
Colomer, V.,
Paladino, S.,
Nitsch, L.,
Rodriguez-Boulan, E.,
and Zurzolo, C.
(1998)
J. Cell Biol.
140,
617-626
18.
Vogel, U.,
Sandvig, K.,
and van Deurs, B.
(1998)
J. Cell Sci.
111,
825-832
19.
Schnitzer, J. E.,
McIntosh, D. P.,
Dvorak, A. M.,
Liu, J.,
and Oh, P.
(1995)
Science
269,
1435-1439
20.
Maxfield, F. R.,
and Mayor, S.
(1997)
Adv. Exp. Med. Biol.
419,
355-364
21.
Mayor, S.,
Sabharanjak, S.,
and Maxfield, F. R.
(1998)
EMBO J.
17,
4626-4638
22.
Chatterjee, S.,
Smith, E. R.,
Hanada, K.,
Stevens, V. L.,
and Mayor, S.
(2001)
EMBO J.
20,
1583-1592
23.
Nichols, B. J.,
Kenworthy, A. K.,
Polishchuk, R. S.,
Lodge, R.,
Roberts, T. H.,
Hirschberg, K.,
Phair, R. D.,
and Lippincott-Schwartz, J.
(2001)
J. Cell Biol.
153,
529-542
24.
Nelson, K. L.,
Raja, S. M.,
and Buckley, J. T.
(1997)
J. Biol. Chem.
272,
12170-12174
25.
Abrami, L.,
Fivaz, M.,
Glauser, P.-E.,
Parton, R. G.,
and van der Goot, F. G.
(1998)
J. Cell Biol.
140,
525-540
26.
Abrami, L.,
Fivaz, M.,
and van Der Goot, F. G.
(2000)
Trends Microbiol.
8,
168-172
27.
Nakamura, N.,
Inoue, N.,
Watanabe, R.,
Takahashi, M.,
Takeda, J.,
Stevens, V. L.,
and Kinoshita, T.
(1997)
J. Biol. Chem.
272,
15834-15840
28.
Tarutani, M.,
Itami, S.,
Okabe, M.,
Ikawa, M.,
Tezuka, T.,
Yoshikawa, K.,
Kinoshita, T.,
and Takeda, J.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
7400-7405
29.
Kurzchalia, T. V.,
Dupree, P.,
Parton, R. G.,
Kellner, R.,
Virta, H.,
Lehnert, M.,
and Simons, K.
(1992)
J. Cell Biol.
118,
1003-1014
30.
Buckley, J. T.
(1990)
Biochem. Cell Biol.
68,
221-224
31.
van der Goot, F. G.,
Hardie, K. R.,
Parker, M. W.,
and Buckley, J. T.
(1994)
J. Cell Biol.
269,
30496-30501
32.
Kuge, O.,
Nishijima, M.,
and Akamatsu, Y.
(1985)
Proc. Natl. Acad. Sci. U. S. A.
82,
1926-1930
33.
Laemmli, U. K.
(1970)
Nature
227,
680-685
34.
Graham, F. L.,
and van der Eb, A. J.
(1973)
Virology
54,
536-539
35.
Harder, T.,
Scheiffele, P.,
Verkade, P.,
and Simons, K.
(1998)
J. Cell Biol.
141,
929-942
36.
Fivaz, M.,
Vilbois, F.,
Pasquali, C.,
and van der Goot, F. G.
(2000)
Electrophoresis
21,
3351-3356
37.
Pasquali, C.,
Fialka, I.,
and Huber, L. A.
(1997)
Electrophoresis
18,
2573-2581
38.
Hailstones, D.,
Sleer, L. S.,
Parton, R. G.,
and Stanley, K. K.
(1998)
J. Lipid Res.
39,
369-379
39.
Diep, D. B.,
Nelson, K. L.,
Raja, S. M.,
McMaster, R. W.,
and Buckley, J. T.
(1998)
J. Cell Biol.
273,
2355-2360
40.
Gordon, V. M.,
Nelson, K. L.,
Buckley, J. T.,
Stevens, V. L.,
Tweten, R. K.,
Elwood, P. C.,
and Leppla, S. H.
(1999)
J. Biol. Chem.
274,
27274-27280
41.
Brodsky, R. A.,
Mukhina, G. L.,
Nelson, K. L.,
Lawrence, T. S.,
Jones, R. J.,
and Buckley, J. T.
(1999)
Blood
93,
1749-1756
42.
Kinoshita, T.,
Ohishi, K.,
and Takeda, J.
(1997)
J Biochem. (Tokyo)
122,
251-257
43.
Stevens, V. L.
(1995)
Biochem. J.
310,
361-370
44.
Stevens, V. L.,
Zhang, H.,
and Harreman, M.
(1996)
Biochem. J.
313,
253-258
45.
Abrami, L.,
Fivaz, M.,
Decroly, E.,
Seidah, N. G.,
François, J.,
Thomas, G.,
Leppla, S.,
Buckley, J. T.,
and van der Goot, F. G.
(1998)
J. Biol. Chem.
273,
32656-32661
46.
Maeda, Y.,
Tomita, S.,
Watanabe, R.,
Ohishi, K.,
and Kinoshita, T.
(1998)
EMBO J.
17,
4920-4929
47.
Kirchhausen, T.
(2000)
Nat. Rev. Mol. Cell. Biol.
1,
187-198
48.
Zerial, M.,
and McBride, H.
(2001)
Nat. Rev. Mol. Cell. Biol.
2,
107-117
49.
Kreis, T. E.,
Lowe, M.,
and Pepperkok, R.
(1995)
Annu. Rev. Cell Dev. Biol.
11,
677-706
50.
Aniento, F., Gu, F., Parton, R. G., and Gruenberg, J. (1996)
133, 29-41
51.
Rojo, M.,
Pepperkok, R.,
Emery, G.,
Kellner, R.,
Stang, E.,
Parton, R. G.,
and Gruenberg, J.
(1997)
J. Cell Biol.
139,
1119-1135
52.
Muniz, M.,
Morsomme, P.,
and Riezman, H.
(2001)
Cell
104,
313-320
53.
Muniz, M.,
and Riezman, H.
(2000)
EMBO J.
19,
10-15
54.
Nozaki, M.,
Ohishi, K.,
Yamada, N.,
Kinoshita, T.,
Nagy, A.,
and Takeda, J.
(1999)
Lab. Invest.
79,
293-299
55.
Bickel, P. E.,
Scherer, P. E.,
Schnitzer, J. E.,
Oh, P.,
Lisanti, M. P.,
and Lodish, H. F.
(1997)
J. Biol. Chem.
272,
13793-13802
56.
Lang, D. M.,
Lommel, S.,
Jung, M.,
Ankerhold, R.,
Petrausch, B.,
Laessing, U.,
Wiechers, M. F.,
Plattner, H.,
and Stuermer, C. A.
(1998)
J. Neurobiol.
37,
502-523
57.
Volonte, D.,
Galbiati, F.,
Li, S.,
Nishiyama, K.,
Okamoto, T.,
and Lisanti, M. P.
(1999)
J. Biol. Chem.
274,
12702-12709
58.
Ferguson, M. A. J.
(1999)
J. Cell Sci.
112,
2799-2809
59.
Sugiyama, E.,
DeGasperi, R.,
Urakaze, M.,
Chang, H. M.,
Thomas, L. J.,
Hyman, R.,
Warren, C. D.,
and Yeh, E. T.
(1991)
J. Biol. Chem.
266,
12119-12122
60.
Harder, T.,
and Kuhn, M.
(2000)
J. Cell Biol.
151,
199-208
61.
van't Hof, W.,
Rodriguez-Boulan, E.,
and Menon, A. K.
(1995)
J. Biol. Chem.
270,
24150-24155
62.
Baumann, N. A.,
Vidugiriene, J.,
Machamer, C. E.,
and Menon, A. K.
(2000)
J. Biol. Chem.
275,
7378-7389
63.
Galbiati, F.,
Volonte, D.,
Engelman, J. A.,
Watanabe, G.,
Burk, R.,
Pestell, R. G.,
and Lisanti, M. P.
(1998)
EMBO J.
17,
6633-6648
64.
Watanabe, R.,
Murakami, Y.,
Marmor, M. D.,
Inoue, N.,
Maeda, Y.,
Hino, J.,
Kangawa, K.,
Julius, M.,
and Kinoshita, T.
(2000)
EMBO J.
19,
4402-4411
65.
Scherer, P. E.,
Lisanti, M. P.,
Baldini, G.,
Sargiacomo, M.,
Mastick, C. C.,
and Lodish, H. F.
(1994)
J. Cell Biol.
1274,
1233-1243
66.
Yang, C. P.,
Galbiati, F.,
Volonte, D.,
Horwitz, S. B.,
and Lisanti, M. P.
(1998)
FEBS Lett.
439,
368-372
67.
Bagnoli, M.,
Tomassetti, A.,
Figini, M.,
Flati, S.,
Dolo, V.,
Canevari, S.,
and Miotti, S.
(2000)
Oncogene
19,
4754-4763
68.
Samuel, B. U.,
Mohandas, N.,
Harrison, T.,
McManus, H.,
Rosse, W.,
Reid, M.,
and Haldar, K.
(2001)
J. Biol. Chem.
276,
29319-29329
Copyright © 2001 by The American Society for Biochemistry and Molecular Biology, Inc.
![]()
CiteULike
Complore
Connotea
Del.icio.us
Digg
Reddit
Technorati What's this?
This article has been cited by other articles:
![]() |
L. Matthews, A. Berry, V. Ohanian, J. Ohanian, H. Garside, and D. Ray Caveolin Mediates Rapid Glucocorticoid Effects and Couples Glucocorticoid Action to the Antiproliferative Program Mol. Endocrinol., June 1, 2008; 22(6): 1320 - 1330. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Kajiwara, R. Watanabe, H. Pichler, K. Ihara, S. Murakami, H. Riezman, and K. Funato Yeast ARV1 Is Required for Efficient Delivery of an Early GPI Intermediate to the First Mannosyltransferase during GPI Assembly and Controls Lipid Flow from the Endoplasmic Reticulum Mol. Biol. Cell, May 1, 2008; 19(5): 2069 - 2082. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Li, D. Kaloyanova, M. van Eijk, R. Eerland, G. van der Goot, V. Oorschot, J. Klumperman, F. Lottspeich, V. Starkuviene, F. T. Wieland, et al. Involvement of a Golgi-resident GPI-anchored Protein in Maintenance of the Golgi Structure Mol. Biol. Cell, April 1, 2007; 18(4): 1261 - 1271. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Schabath, S. Runz, S. Joumaa, and P. Altevogt CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells J. Cell Sci., January 15, 2006; 119(2): 314 - 325. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Y. Kang, Y. Hong, H. Ashida, N. Shishioh, Y. Murakami, Y. S. Morita, Y. Maeda, and T. Kinoshita PIG-V Involved in Transferring the Second Mannose in Glycosylphosphatidylinositol J. Biol. Chem., March 11, 2005; 280(10): 9489 - 9497. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chasserot-Golaz, N. Vitale, E. Umbrecht-Jenck, D. Knight, V. Gerke, and M.-F. Bader Annexin 2 Promotes the Formation of Lipid Microdomains Required for Calcium-regulated Exocytosis of Dense-Core Vesicles Mol. Biol. Cell, March 1, 2005; 16(3): 1108 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Monastyrskaya, A. Hostettler, S. Buergi, and A. Draeger The NK1 Receptor Localizes to the Plasma Membrane Microdomains, and Its Activation Is Dependent on Lipid Raft Integrity J. Biol. Chem., February 25, 2005; 280(8): 7135 - 7146. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. G. van der Goot, G. T. van Nhieu, A. Allaoui, P. Sansonetti, and F. Lafont Rafts Can Trigger Contact-mediated Secretion of Bacterial Effectors via a Lipid-based Mechanism J. Biol. Chem., November 12, 2004; 279(46): 47792 - 47798. [Abstract] [Full Text] [PDF] |
||||
![]() |